Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Nadeem Riaz, Jonathan J. Havel, Vladimir Makarov, +22

Cell

Microenvironment EvolutionTumor ImmunologyCancer ImmunosurveillanceImmunologyImmune Checkpoint Inhibitor +4

A Landscape of Pharmacogenomic Interactions in Cancer

Francesco Iorio, Theo Knijnenburg, Daniël J. Vis, +36

Cell

Tumor BiologyOncologyTumor HeterogeneityMedicineDrug Response +11

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

David R. Spigel, David Vicente, Tudor–Eliade Ciuleanu, +19

Annals of Oncology

Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy

Kexin Chen, Da Yang, Xiangchun Li, +29

Proceedings of the National Academy of Sciences

Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy

Megan M. Tu, Francis Y. F. Lee, Robert T. Jones, +20

Science Advances

Machine Learning Algorithms for the Prediction of Central Lymph Node Metastasis in Patients With Papillary Thyroid Cancer

Yijun Wu, Ke Rao, Jianghao Liu, +5

Frontiers in Endocrinology

Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

Martin Reck, David Vicente, Tudor–Eliade Ciuleanu, +16

Annals of Oncology

Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026

Solange Peters, Ben Creelan, Matthew D. Hellmann, +7

Cancer Research

Abstract Ct082Tumor Mutation BurdenMedicinePathologyTmb Scores +10

Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer

Ming Lei, Nathan O. Siemers, Dimple Pandya, +12

Clinical Cancer Research

Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568

Suresh S. Ramalingam, Matthew D. Hellmann, Mark M. Awad, +15

Cancer Research

ImmunologyPathologyImmunotherapeuticsImmunotherapyOncology +15